In November, regulators overseeing pharmaceutical standards in the U.S. identifi...
Gilead Sciences has agreed to purchase CymaBay Therapeutics for $4.3 billion, ai...
Unlearn, a developer specializing in digital replicas, recently disclosed its at...
Johnson & Johnson’s recent triumph with its $6.5 billion autoimmune medication i...
The recent buzz surrounding a potential bidding war for the cancer specialist Mo...
A Chinese biotechnology company’s experimental gene therapy has demonstrated enc...
In an unforeseen development, the FDA’s directive for a labeling alteration conc...
Novo Nordisk has announced its highest annual profit in decades, attributing it ...
Defender Pharmaceuticals, headquartered in St. Louis, faces a setback in its que...
It appears that Sarepta Therapeutics’ upcoming treatment for Duchenne muscular d...
A non-opioid pain reliever has demonstrated efficacy in two extensive clinical t...
Novo Nordisk has signed a partnership with EraCal Therapeutics, a Swiss biotech ...
Gilead encountered a significant setback concerning its antibody-drug conjugate ...
Sanofi, the prominent pharmaceutical conglomerate, has undertaken a recent merge...
Surrozen finds itself at a crossroads in its pursuit of a treatment for inflamma...
AM-Pharma B.V. announced that the first individuals have been given treatment in...
